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Background

Reduced time to antibiotics has been shown to
improve outcomes in patients with sepsis (Fletcher
et.al, 2013).













A key limitation was the small sample size of 21
patients.



Assigning an ESI-2 triage acuity is recommended as
lengthy delays were noted with ESI-3 patients (Figure
4).



Time delays are spread throughout the DTA timeline
suggesting that multiple workflow barriers exist
throughout the ED encounter (Figure 2).



Future projects should focus on process improvement
towards rapid identification of febrile neutropenia,
timely antibiotic orders and delivery as well as nursing
education.



Despite controversial outcomes related to door to
antibiotic times in NF patients, the expert
recommendation and current standard of practice
uphold that initiation of antibiotics be administered
within 60 minutes (Taplitz et.al, 2018 & Flowers et.al,
2013).

The Providence Oregon Regional Institutional Review Board
approved this project.



This was a retrospective chart review of adult cancer patients
admitted with NF from PPMC’s ED to inpatient units between
January 1st, 2018 to December 31st, 2019.

Results



Inclusion criteria used to define the study population consisted
of: age of at least 18 years old, active cancer diagnosis,
received chemotherapy within 14 days of presentation to the
ED, absolute neutrophil count (ANC) of less than or equal to
1,000pu/L, and an oral temperature of equal to or greater than
38.1 C.



21 patients met inclusion criteria for this project.



The average DTA time was 152 minutes with a range
between 72 and 260 minutes (Figure 1).
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The 2 outliers with the longest DTA times were mistriaged at a lower acuity of ESI-3.
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On arrival to the ED, patients self identified a risk factor of
cancer, chemotherapy, or fever between 67 – 95% of the
time.
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NF patients frequently present to Emergency
Department (ED) settings for evaluation and
treatment ( Bow et.al, 2019).

Data points included door to antibiotic (DTA) times, early
identification of risk factors in triage note, demographics, vital
signs, triage acuity using Emergency Severity Index (ESI) with
1 being higher acuity than 5, types of venous access, and
times of blood draws, and antibiotic orders.

As a result, increased length of stay, increased risk
for adverse events, sepsis and even death can occur
(Koenig et.al, 2019).
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Delays were spread evenly between blood draw, ANC
result, antibiotic order, and antibiotic delivery (Figure 2).



Studies confirm significant delays in antibiotic
administration, associated with NF patients, occur in
the ED setting (Koenig et.al, 2019).

Providence Portland Medical Center’s (PPMC) 46bed ED is where cancer patients commonly present
with NF and are provided nursing and medical care.

There were no significant DTA discrepancies between
select populations except for ESI acuity (Figure 4).
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Lengthy DTA times suggest interventions are needed
to address delays.

Methods

Vigilant nursing assessment and immediate medical
attention for neutropenic fever (NF) is imperative
because the rate of major organ complication and
mortality is as high as 30% and 11% respectively
(Freifield et.al, 2011 & Taplitz et.al, 2018).
In the setting of severe sepsis or septic shock the
mortality rate may be as high as 50% (Taplitz et.al,
2018).



patients presenting with NF who are admitted through PPMC’s ED.

Fever is often the only sign of severe underlying
infection in neutropenic patients due to the patient’s
immunosuppressed state (Butts, et.al, 2017).



The purpose of this study is to assess the door to antibiotic times, based
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Discussion/Conclusions

on current standards of care of a 60-minute time frame, for cancer

Combined ESI 2 and 3



Infection, related to febrile neutropenia, in patients
receiving chemotherapy for cancer remains a
common complication and is a medical emergency.
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Purpose

Freifeld, A.G., Bow, E.J.,Sepkowitz, K.A., et. al. (2011). Clinical practice guideline for
the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by
Infectious Diseases Society of America. Clinical Infectious Diseases, 52: e56-e93.
Koenig, C., Schneider, C., Morgan, J.E., Ammann, R.A., Sung, L. Phillips, B. (2019).
Association of time to antibiotics and clinical outcomes inpatients with fever and
neutropenia during chemotherapy for cancer: a systematic review. Supportive Care in
Cancer. https://doi.org/10.1007/s00520-019-014961-4.
Taplitz, R.A., Kennedy, E.R., Bow, E.J. (2018). Antimicrobial prophylaxis for adult
patients with cancer-related immunosuppression:ASCO and IDSA clinical practice
guideline update. J of Clinical Oncology, 36(30):3043-3054.
Taplitz, R.A., Kennedy, E.B. and Flowers, C.R. (2018). Outpatient management of
fever and neutropenia in adults treated for malignancy: American Society of Clinical
Oncology and Infectious Diseases Society of America clinical guideline update
summary. J of Oncology Practice, 18(4):250-256.
Other references available upon request.

